Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.
Acute Lung Injury
/ metabolism
Animals
Cyclic Nucleotide Phosphodiesterases, Type 4
/ metabolism
Cytokines
/ metabolism
Hypothermia
/ metabolism
Lung
/ metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
Phosphodiesterase 4 Inhibitors
/ pharmacology
Pseudomonas Infections
/ metabolism
Pseudomonas aeruginosa
/ pathogenicity
Signal Transduction
/ physiology
Tumor Necrosis Factor-alpha
/ metabolism
Pseudomonas aeruginosa
PDE4B
acute lung injury
cytostorm
hypothermia
interleukin 6
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
24
06
2021
received:
23
03
2021
accepted:
29
06
2021
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
Pseudomonas aeruginosa is a frequent cause of hospital-acquired lung infections characterized by hyperinflammation, antibiotic resistance, and high morbidity/mortality. Here, we show that the genetic ablation of one cAMP-phosphodiesterase 4 subtype, PDE4B, is sufficient to protect mice from acute lung injury induced by P aeruginosa infection as it reduces pulmonary and systemic levels of pro-inflammatory cytokines, as well as pulmonary vascular leakage and mortality. Surprisingly, despite dampening immune responses, bacterial clearance in the lungs of PDE4B-KO mice is significantly improved compared to WT controls. In wildtypes, P aeruginosa-infection produces high systemic levels of several cytokines, including TNF-α, IL-1β, and IL-6, that act as cryogens and render the animals hypothermic. This, in turn, diminishes their ability to clear the bacteria. Ablation of PDE4B curbs both the initial production of acute response cytokines, including TNF-α and IL-1β, as well as their downstream signaling, specifically the induction of the secondary-response cytokine IL-6. This synergistic action protects PDE4B-KO mice from the deleterious effects of the P aeruginosa-induced cytostorm, while concurrently improving bacterial clearance, rather than being immunosuppressive. These benefits of PDE4B ablation are in contrast to the effects resulting from treatment with PAN-PDE4 inhibitors, which have been shown to increase bacterial burden and dissemination. Thus, PDE4B represents a promising therapeutic target in settings of P aeruginosa lung infections.
Identifiants
pubmed: 34383981
doi: 10.1096/fj.202100495R
pmc: PMC8424872
mid: NIHMS1733104
doi:
Substances chimiques
Cytokines
0
Phosphodiesterase 4 Inhibitors
0
Tumor Necrosis Factor-alpha
0
Cyclic Nucleotide Phosphodiesterases, Type 4
EC 3.1.4.17
PDE4B protein, mouse
EC 3.1.4.17
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21797Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL076125
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL066299
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141473
Pays : United States
Informations de copyright
© 2021 Federation of American Societies for Experimental Biology.
Références
Nat Rev Drug Discov. 2019 Oct;18(10):770-796
pubmed: 31388135
J Cell Sci. 2014 Mar 1;127(Pt 5):1033-42
pubmed: 24413164
PLoS One. 2016 Mar 03;11(3):e0150606
pubmed: 26938654
Handb Clin Neurol. 2018;156:3-43
pubmed: 30454596
Physiol Behav. 2017 Oct 1;179:55-66
pubmed: 28533176
Microbiol Immunol. 1982;26(1):15-24
pubmed: 7087800
Front Biosci. 2005 Sep 01;10:2193-216
pubmed: 15970487
Biochem Pharmacol. 2021 Apr;186:114477
pubmed: 33609559
Am J Respir Cell Mol Biol. 2016 Jul;55(1):24-34
pubmed: 26677751
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
J Intensive Care. 2014 Feb 18;2(1):10
pubmed: 25520826
Biochem Pharmacol. 2020 Oct;180:114158
pubmed: 32702371
J Pharmacol Exp Ther. 2016 Apr;357(1):66-72
pubmed: 26865680
Front Biosci. 2004 May 01;9:1877-88
pubmed: 14977594
J Allergy Clin Immunol. 2010 Dec;126(6):1252-9.e12
pubmed: 21047676
J Biol Chem. 2011 Apr 8;286(14):12590-601
pubmed: 21288894
Br J Pharmacol. 2003 Nov;140(5):855-62
pubmed: 14585803
Biochem J. 2014 May 1;459(3):539-50
pubmed: 24555506
Expert Opin Ther Targets. 2013 Sep;17(9):1011-27
pubmed: 23883342
Pharmacol Res. 2020 Sep;159:105030
pubmed: 32562817
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7628-33
pubmed: 12032334
Nat Rev Microbiol. 2009 Sep;7(9):654-65
pubmed: 19680249
Front Microbiol. 2020 Aug 27;11:2057
pubmed: 32973737
J Clin Invest. 2002 Oct;110(7):1045-52
pubmed: 12370283
Crit Care Med. 2003 Dec;31(12):2811-2
pubmed: 14668624
J Biol Chem. 2017 Aug 18;292(33):13758-13773
pubmed: 28655761
PLoS One. 2014 Feb 24;9(2):e89941
pubmed: 24587139
J Biol Chem. 2003 Feb 21;278(8):5493-6
pubmed: 12493749
Biochem Biophys Res Commun. 2014 Aug 8;450(4):1560-7
pubmed: 25019986
Front Pharmacol. 2018 Oct 17;9:1048
pubmed: 30386231
FASEB J. 2020 Sep;34(9):12533-12548
pubmed: 32738081
J Pharmacol Sci. 2013;123(3):219-26
pubmed: 24152964
J Immunol. 2005 Aug 1;175(3):1523-31
pubmed: 16034090
Am J Respir Cell Mol Biol. 2013 Oct;49(4):503-10
pubmed: 23672262
Cardiovasc Res. 2014 May 1;102(2):258-69
pubmed: 24728497
Curr Opin Microbiol. 2009 Feb;12(1):61-6
pubmed: 19168385
J Immunol. 2004 Dec 15;173(12):7531-8
pubmed: 15585880
PLoS One. 2013 Jul 01;8(7):e69123
pubmed: 23840908
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15562-7
pubmed: 25313031
Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1244-52
pubmed: 16081879
Handb Clin Neurol. 2018;157:565-597
pubmed: 30459026
Expert Opin Emerg Drugs. 2014 Sep;19(3):323-8
pubmed: 25152048
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12791-6
pubmed: 18728186
J Pathol Bacteriol. 1956 Apr;71(2):353-8
pubmed: 13398880
Drug Discov Today. 2005 Nov 15;10(22):1503-19
pubmed: 16257373
Crit Care Med. 2014 Feb;42(2):231-42
pubmed: 23989182
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Expert Opin Ther Targets. 2005 Dec;9(6):1283-305
pubmed: 16300476
J Neuroinflammation. 2016 Nov 4;13(1):284
pubmed: 27809877
Infect Control Hosp Epidemiol. 2015 Oct;36(10):1190-7
pubmed: 26190444